SCHEMBL3452142

SCHEMBL3452142

CC(=O)Nc1ccc2nc(Nc3ccccc3)oc(=O)c2c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 4/20 0.60
KMT2A Q03164 5/20 0.56
MEN1 O00255 4/20 0.56
MAPK10 P53779 1/20 0.56
KDM4E B2RXH2 8/20 0.54
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54
ALDH1A1 P00352 3/20 0.54
LMNA P02545 2/20 0.54
HPGD P15428 1/20 0.54
MAPT P10636 5/20 0.51
PABPC1 P11940 1/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
POLB P06746 3/20 0.50
KDM1A O60341 2/20 0.50
MITF O75030 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10749568 0.83 ELANE (0.62) ELANEKMT2AMEN1MAPK10KDM4E
SCHEMBL10745487 0.82 ELANE (0.82) ELANEKMT2AMEN1MAPK10CASP3
SCHEMBL3452649 0.80 ELANE (0.68) ELANEKMT2AMEN1KDM4ENPC1
SCHEMBL10747463 0.79 ELANE (0.61) ELANEKMT2AMEN1MAPK10NPC1
SCHEMBL3453029 0.78 NPC1 (0.71) ELANEKDM4ENPC1RAB9AALDH1A1
SCHEMBL3453309 0.78 ELANE (0.68) ELANEKDM4ENPC1RAB9AALDH1A1
SCHEMBL3453469 0.78 ELANE (0.68) ELANEKDM4ENPC1RAB9AALDH1A1
SCHEMBL13224725 0.77 ELANE (0.63) ELANEKDM4ENPC1RAB9AALDH1A1
SCHEMBL6229437 0.77 ELANE (0.63) ELANEKDM4ENPC1RAB9AALDH1A1
SCHEMBL3452604 0.76 ELANE (1.00) ELANEKDM4ENPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1144395-B1 2-AMINO-BENZOXAZINONE DERIVATIVES FOR THE TREATMENT OF OBESITY ALIZYME THERAPEUTICS LTD (GB) 2005-04-20 EP claimed
US-6656934-B2 Enzyme inhibitor ALIZYME THERAPEUTICS LIMITED (GB) 2003-12-02 US claimed
US-20030191123-A1 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2003-10-09 US claimed
US-20030013707-A1 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2003-01-16 US claimed
US-7776853-B2 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2010-08-17 US disclosed
US-7776853-B2 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2010-08-17 US disclosed
US-7776853-B2 2-amino-benzoxazinone derivatives for the treatment of obesity NORGINE B.V. (NL) 2010-08-17 US disclosed
US-6656934-B2 Enzyme inhibitor ALIZYME THERAPEUTICS LIMITED (GB) 2003-12-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030191123-A1 2-amino-benzoxazinone derivatives for the treatment of obesity CYP4X1, CYP2B6, BBOX1 ELANE 730/4885KMT2A 1406/4885MEN1 4610/4885
US-20030013707-A1 2-amino-benzoxazinone derivatives for the treatment of obesity CYP4X1, CYP2B6, BBOX1 ELANE 730/4885KMT2A 1406/4885MEN1 4610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.